Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review

Author： Pulla Venkat Koushik   Battu Madhu Babu   Alvala Mallika   Sriram Dharmarajan   Yogeeswari Perumal  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.16, Iss.8, 2012-08, pp. : 819-832

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes

By  

Current Bioactive Compounds, Vol. 4, Iss. 2, 2008-01 ,pp. : 68-85

Bentham Science Publishers

Access to resources Recommend Favorite

SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 10, Iss. 1, 2010-03 ,pp. : 16-24

Bentham Science Publishers

Access to resources Recommend Favorite

Can Modulating Inflammatory Response be a Good Strategy to Treat Neuropathic Pain?

By  

Current Pharmaceutical Design, Vol. 21, Iss. 7, 2015-02 ,pp. : 831-839

Bentham Science Publishers

Access to resources Recommend Favorite

Good and bad sides of viruses in Type 1 diabetes

By Filippi Christophe M   von Herrath Matthias G  

Future Virology, Vol. 4, Iss. 5, 2009-09 ,pp. : 407-410

Future Medicine

Access to resources Recommend Favorite

Liraglutide looking good in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite